Teva Pharmaceutical Industries Ltd (TEVA) stock
TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30113% above fair value
$43.24+0.84 (+1.98%)
Close on Nov 11, 2026Market cap $50.39BP/E 72.1Yield –
Teva Pharmaceutical Industries gross margin
Gross margin is gross profit as a percentage of revenue.
Teva Pharmaceutical Industries's gross margin for the twelve months ending Jun 30, 2026 was 64.4%. For fiscal 2025 it was 51.8%, against 48.7% the year before. The highest annual figure on record is 57.8% in fiscal 2015.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 51.8% | +3.0 |
| FY2024 | Dec 31, 2024 | 48.7% | +0.5 |
| FY2023 | Dec 31, 2023 | 48.2% | +1.5 |
| FY2022 | Dec 31, 2022 | 46.7% | −1.1 |
| FY2021 | Dec 31, 2021 | 47.8% | +1.4 |
| FY2020 | Dec 31, 2020 | 46.4% | +1.7 |
| FY2019 | Dec 31, 2019 | 44.6% | −0.8 |
| FY2018 | Dec 31, 2018 | 45.4% | −3.2 |
| FY2017 | Dec 31, 2017 | 48.6% | −4.6 |
| FY2016 | Dec 31, 2016 | 53.2% | −4.6 |
| FY2015 | Dec 31, 2015 | 57.8% | +3.2 |
| FY2014 | Dec 31, 2014 | 54.5% | +1.8 |
| FY2013 | Dec 31, 2013 | 52.7% | +0.3 |
| FY2012 | Dec 31, 2012 | 52.4% | +0.5 |
| FY2011 | Dec 31, 2011 | 52.0% | −4.3 |
| FY2010 | Dec 31, 2010 | 56.2% | +10.5 |
| FY2009 | Dec 31, 2009 | 45.7% | −8.1 |
| FY2008 | Dec 31, 2008 | 53.8% | +2.0 |
| FY2007 | Dec 31, 2007 | 51.8% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 52.0% | +1.6 |
| Q1 FY2026 | Mar 31, 2026 | 49.5% | +1.3 |
| Q4 FY2025 | Dec 31, 2025 | 177.1% | +126.9 |
| Q3 FY2025 | Sep 30, 2025 | 51.4% | +1.8 |
| Q2 FY2025 | Jun 30, 2025 | 50.3% | +1.7 |
| Q1 FY2025 | Mar 31, 2025 | 48.2% | +1.9 |
| Q4 FY2024 | Dec 31, 2024 | 50.2% | −4.0 |
| Q3 FY2024 | Sep 30, 2024 | 49.6% | +1.5 |
| Q2 FY2024 | Jun 30, 2024 | 48.6% | +2.3 |
| Q1 FY2024 | Mar 31, 2024 | 46.4% | +3.2 |
| Q4 FY2023 | Dec 31, 2023 | 54.2% | +8.6 |
| Q3 FY2023 | Sep 30, 2023 | 48.1% | +1.7 |
| Q2 FY2023 | Jun 30, 2023 | 46.3% | −1.1 |
| Q1 FY2023 | Mar 31, 2023 | 43.2% | −4.3 |
| Q4 FY2022 | Dec 31, 2022 | 45.6% | −4.4 |
| Q3 FY2022 | Sep 30, 2022 | 46.4% | +0.3 |
| Q2 FY2022 | Jun 30, 2022 | 47.4% | −0.5 |
| Q1 FY2022 | Mar 31, 2022 | 47.5% | +0.4 |
| Q4 FY2021 | Dec 31, 2021 | 50.0% | +4.0 |
| Q3 FY2021 | Sep 30, 2021 | 46.2% | −0.4 |
| Q2 FY2021 | Jun 30, 2021 | 47.9% | +2.3 |
| Q1 FY2021 | Mar 31, 2021 | 47.2% | −0.2 |
| Q4 FY2020 | Dec 31, 2020 | 46.0% | +2.2 |
| Q3 FY2020 | Sep 30, 2020 | 46.6% | +1.8 |
| Q2 FY2020 | Jun 30, 2020 | 45.6% | +0.2 |
| Q1 FY2020 | Mar 31, 2020 | 47.3% | +2.6 |
| Q4 FY2019 | Dec 31, 2019 | 43.8% | −0.8 |
| Q3 FY2019 | Sep 30, 2019 | 44.7% | −0.4 |
| Q2 FY2019 | Jun 30, 2019 | 45.3% | +0.7 |
| Q1 FY2019 | Mar 31, 2019 | 44.7% | −2.4 |
| Q4 FY2018 | Dec 31, 2018 | 44.6% | −0.7 |
| Q3 FY2018 | Sep 30, 2018 | 45.1% | −1.2 |
| Q2 FY2018 | Jun 30, 2018 | 44.7% | −4.3 |
| Q1 FY2018 | Mar 31, 2018 | 47.1% | −1.9 |
| Q4 FY2017 | Dec 31, 2017 | 45.3% | −6.9 |
| Q3 FY2017 | Sep 30, 2017 | 46.3% | −4.1 |
| Q2 FY2017 | Jun 30, 2017 | 49.0% | – |
| Q1 FY2017 | Mar 31, 2017 | 49.0% | – |
| Q4 FY2016 | Dec 31, 2016 | 52.2% | – |
| Q3 FY2016 | Sep 30, 2016 | 50.4% | – |
See a number that looks wrong?